Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CTXR
stocks logo

CTXR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.240
-95.86%
--
--
4.500
-446.15%
--
--
4.500
-454.33%
Estimates Revision
The market is revising No Change the revenue expectations for Citius Pharmaceuticals, Inc. (CTXR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 1.63%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+1.63%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Citius Pharmaceuticals Inc (CTXR.O) is 1.38, compared to its 5-year average forward P/E of -5.08. For a more detailed relative valuation and DCF analysis to assess Citius Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.08
Current PE
1.38
Overvalued PE
12.46
Undervalued PE
-22.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.38
Current PS
0.00
Overvalued PS
10.23
Undervalued PS
-1.46
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CTXR News & Events

Events Timeline

(ET)
2025-12-01
12:10:00
Citius Oncology Launches LYMPHIR for Skin T-Cell Lymphoma Treatment
select
2025-11-21 (ET)
2025-11-21
08:40:30
Citius Oncology to expedite Lymphir launch by incorporating Verix AI technology
select
2025-10-21 (ET)
2025-10-21
08:03:22
Citius Pharmaceuticals Reveals $6M Registered Direct Offering at ATM Pricing
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-04PRnewswire
Citius Oncology Partners with Er-Kim for Exclusive LYMPHIR Distribution in GCC Countries
  • Market Expansion: Citius Oncology's exclusive distribution agreement with Turkey's Er-Kim significantly enhances access to LYMPHIR across Turkey and six Gulf Cooperation Council countries, expanding its reach to a total of 19 international markets, which is expected to meet the urgent demand for innovative oncology treatments in the region.
  • Strategic Partnership: Leveraging Er-Kim's extensive experience in complex international markets, the company will manage sales, marketing, and reimbursement activities for LYMPHIR, ensuring successful implementation in emerging markets and enhancing Citius Oncology's competitiveness in the global oncology landscape.
  • Product Supply: Under the agreement, Citius Oncology will supply finished LYMPHIR products and support Er-Kim's marketing efforts, accelerating the drug's penetration into new markets and potentially driving revenue growth for the company.
  • Commitment to Innovation: This partnership underscores Citius Oncology's dedication to broadening access to innovative oncology therapies through strategic collaborations with experienced global partners, further solidifying its position in the international market.
[object Object]
Preview
5.0
12-02PRnewswire
Citius Oncology Launches LYMPHIR, Addressing CTCL Treatment Gap
  • New Drug Launch: Citius Oncology announces the nationwide launch of LYMPHIR™ (denileukin diftitox-cxdl) in the U.S., filling a critical treatment gap for relapsed or refractory cutaneous T-cell lymphoma (CTCL) in a market valued at over $400 million, addressing a clear clinical need.
  • Significant Clinical Efficacy: In Phase 3 trials, LYMPHIR demonstrated an Objective Response Rate (ORR) of 36.2%, with 84% of evaluable patients experiencing a reduction in skin tumor burden, highlighting its potential to improve patient quality of life.
  • Rapid Response Time: The median time to response for LYMPHIR is 1.4 months, providing patients with quick skin relief, marking a significant advancement for Citius Oncology in the CTCL treatment landscape.
  • International Market Expansion: Citius Oncology has signed a distribution agreement with Integris Pharma S.A. to initiate named-patient access programs in Greece, Cyprus, and other Southern European and Balkan countries, enhancing global patient access to LYMPHIR.
[object Object]
Preview
5.0
12-02Newsfilter
Citius Oncology Launches LYMPHIR, Targeting $400 Million Market
  • Product Launch: Citius Oncology has officially launched LYMPHIR™ (denileukin diftitox-cxdl) in the U.S., marking it as the first new treatment option for relapsed or refractory cutaneous T-cell lymphoma, addressing a significant unmet clinical need.
  • Clinical Efficacy: In Phase 3 trials, LYMPHIR demonstrated an objective response rate of 36.2%, with 84% of patients experiencing a significant reduction in skin tumor burden, which is expected to provide rapid skin relief and improve quality of life for patients.
  • Market Potential: LYMPHIR enters a U.S. market valued at over $400 million, with substantial growth opportunities through international market access and potential expanded indications, positioning it as a value-driving catalyst for Citius Oncology shareholders.
  • Distribution Network: LYMPHIR is now available through specialty distributors nationwide and has been included in the National Comprehensive Cancer Network (NCCN) guidelines, ensuring easier access to treatment for patients and enhancing the company's competitive position in the market.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Citius Pharmaceuticals Inc (CTXR) stock price today?

The current price of CTXR is 1.25 USD — it has increased 9.17 % in the last trading day.

arrow icon

What is Citius Pharmaceuticals Inc (CTXR)'s business?

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

arrow icon

What is the price predicton of CTXR Stock?

Wall Street analysts forecast CTXR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTXR is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Citius Pharmaceuticals Inc (CTXR)'s revenue for the last quarter?

Citius Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Citius Pharmaceuticals Inc (CTXR)'s earnings per share (EPS) for the last quarter?

Citius Pharmaceuticals Inc. EPS for the last quarter amounts to -0.80 USD, decreased -49.04 % YoY.

arrow icon

What changes have occurred in the market's expectations for Citius Pharmaceuticals Inc (CTXR)'s fundamentals?

The market is revising No Change the revenue expectations for Citius Pharmaceuticals, Inc. (CTXR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 1.63%.
arrow icon

How many employees does Citius Pharmaceuticals Inc (CTXR). have?

Citius Pharmaceuticals Inc (CTXR) has 23 emplpoyees as of December 05 2025.

arrow icon

What is Citius Pharmaceuticals Inc (CTXR) market cap?

Today CTXR has the market capitalization of 23.09M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free